Author: Shedlock, Devon J.; Bailey, Michael A.; Popernack, Paul M.; Cunningham, James M.; Burton, Dennis R.; Sullivan, Nancy J.
Title: Antibody-mediated Neutralization of Ebola Virus Can Occur by Two Distinct Mechanisms Cord-id: 2piazw0l Document date: 2010_6_1
ID: 2piazw0l
Snippet: Human Ebola virus (EBOV) causes severe hemorrhagic fever disease with high mortality and there is no vaccine or treatment. Antibodies in survivors occur early, are sustained, and can delay infection when transferred into nonhuman primates. Monoclonal antibodies (mAbs) from survivors exhibit potent neutralizing activity in vitro and are protective in rodents. To better understand targets and mechanisms of neutralization, we investigated a panel of mAbs shown previously to react with the envelope
Document: Human Ebola virus (EBOV) causes severe hemorrhagic fever disease with high mortality and there is no vaccine or treatment. Antibodies in survivors occur early, are sustained, and can delay infection when transferred into nonhuman primates. Monoclonal antibodies (mAbs) from survivors exhibit potent neutralizing activity in vitro and are protective in rodents. To better understand targets and mechanisms of neutralization, we investigated a panel of mAbs shown previously to react with the envelope glycoprotein (GP). While one non-neutralizing mAb recognized a GP epitope in the non-essential mucin-like domain, the rest were specific for GP1, were neutralizing, and could be further distinguished by reactivity with secreted GP. We show that survivor antibodies, human KZ52 and monkey JP3K11, were specific for conformation-dependent epitopes comprising residues in GP1 and GP2 and that neutralization occurred by two distinct mechanisms; KZ52 inhibited cathepsin cleavage of GP whereas JP3K11 recognized the cleaved, fusion-active form of GP.
Search related documents:
Co phrase search for related documents- absence presence and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- absence presence and adaptive immunity: 1, 2, 3, 4
- absence presence and additional target: 1
- absence presence and luciferase activity: 1, 2, 3, 4, 5
- absence presence and luciferase reporter: 1, 2, 3, 4, 5
- absence presence and luciferase reporter gene: 1, 2
- absence presence and lysis buffer: 1, 2, 3, 4, 5
- absence presence and mabs presence: 1
- acetate buffer and acute respiratory syndrome: 1
- acetate buffer and luciferase activity: 1
- acetate buffer and luciferase reporter: 1
- acetate buffer and luciferase reporter activity: 1
- acetate buffer and lysis buffer: 1, 2
- activate form and acute respiratory syndrome: 1
- activate form and adaptive immunity: 1
- acute respiratory syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute respiratory syndrome and add antibody: 1, 2
- acute respiratory syndrome and additional target: 1, 2, 3, 4, 5
- acute respiratory syndrome and loading dye: 1
Co phrase search for related documents, hyperlinks ordered by date